1 / 16

Estrogen Therapy in Postmenopausal Women

Estrogen Therapy in Postmenopausal Women. 3/21/08 By Lindsey Boll Advisor: Dr. Hadley PAS 646. Background. Many ET studies HERS WHI ET Controversy Health risks Current perspective Uncertain and fluctuating Needs clarification. Objectives. Physiology HERS and WHI Study Results

parley
Télécharger la présentation

Estrogen Therapy in Postmenopausal Women

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Estrogen Therapy in Postmenopausal Women 3/21/08 By Lindsey Boll Advisor: Dr. Hadley PAS 646

  2. Background • Many ET studies • HERS • WHI • ET Controversy • Health risks • Current perspective • Uncertain and fluctuating • Needs clarification

  3. Objectives • Physiology • HERS and WHI Study Results • Misconceptions • Risk and Benefit analysis • Approach to postmenopausal patient

  4. Physiology • Perimenopause- time of transition characterized by irregularity of menstrual cycle • Ovarian follicular depletion Fluctuating hormone levels Sx • Menopause- permanent cessation of menses • ~51 yo + 2 yrs • Dx by 12 mo ammenorrhea

  5. Physiology • Postmenopause- stage of life after menopause • Ovaries inactive • No estrogen/progesterone produced • PMP Sx result from this hormone deficiency • ~30% of women in U.S. > 50yo (PMP) • Life expectancy: 82 yrs Many women in need of many yrs of PMP care

  6. Physiology • PMP Signs & Symptoms: • GU atrophy w/: • Epithelial thinning, dryness, and inflammation • CNS Sx, such as • Insomnia, mood changes, fatigue • Reduced bone mass, increased fx risk • (vasomotor symptoms- perimenopause) • Hot flashes

  7. Hx of Estrogen Therapy • Many trials (since 1970s) • PEPI 1995 • HERS 1998 and 2002 • ERA 2000 • WHI 2002 and 2004 • Others

  8. HERS Results • Increased risk of venous thromboembolic events • DVT and PE • Increased incidence of gall bladder disease • Favorable effects on lipids and fibrinogen • No sig difference between HT and placebo concerning CHD events

  9. WHI Results • Increased risk in nonfatal CHD events in healthy women • Increased risk of incident breast cancer • Reduction in incidence of fractures • But… • only used one drug regimen • PMP participants included a wide age range from 50yo to 79yo. • Time of initiation of therapy was not taken into consideration

  10. Misconceptions corrected • Significant public consequences: • 2002-03: 43% reduction in ET Rx • HERS Facts • “no cardioprotective effects.” • No difference in CVD events b/t Ht and placebo • WHI: Facts to consider • Dosing factors affect risks/benefits • drug type, route, dosage, administration • Patient profile factors: • Time of HT initiation after menopause, age, and comorbidies

  11. Risks Ovarian cancer Venous thromboembolic events Breast cancer Gall bladder disease Benefits GU atrophy relief Decreased risk of fractures Favorable lipids effects Decreased risk of colorectal cancer Decreased risk of diabetes Overall Risks & Benefits • CHD event risks addressed by early initiation of therapy • Endometrial hyperplasia/cancer addressed by combo therapy with progesterone

  12. Approach to PMP patient seeking HT • Health Provider role • Patient education • Facts on ET, discount myths • True risks and benefits • Patient Treatment with ET • Accurate patient evaluation • Patient PMH • Patient complaints

  13. Patient Evaluation • Contraindications • Unusual vaginal bleeding • Hx of blood clots • Hx of breast cancer • Liver dysfunction • CHD • Studies show that women with CHD and women without CHD are both at risk for CV events, regardless of prior CHD status

  14. Patient Evaluation • Sx Indications in PMP • Urogenital atrophy • Osteoporosis • Colorectal cancer • (Absent contraindications) • Early initiation- during perimenopause • Combined with Progesterone-if uterus intact • Tailor HT type, route, dosage, and administration to individual patient based on age, yrs since menopause, and comorbid conditions.

  15. References • Alessandri N, Piccioni MG, Isabelli V, Alessandri G, Di Matteo A, Padovani D, Rondoni G, Camardella B, Parlapiano C. Morphological and functional changes of cardiovascular system in postmenopausal women. Mar-Apr 2007. Eur Rev Med Pharmacol Sci 11(2):107-17. • Arias, E. United States Life Tables. 2003. National Vital Statitics Report 54:14. Updated 2007. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf. Accessed on 2/29/08. • Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Jan 2008. Obstet Gynecol 111(1):67-76. • Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. 2003. Lancet 362(9382): 419–427. • Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. Jul 2007. J Sex Med 4(1):859-66. • Brett, KM, Chong Y. Hormone replacement therapy: knowledge and use in the United States. Hyattsville, MD. National Center for Health Statistics. 2001. Available at: http://www.cdc.gov/nchs/data/misc/hrt_booklet.PDF, Accessed on 2/29/08. • Contreras, I., Parra, D. Heart and estrogen/progestin replacement study. 2000. Am J Health-Syst Pharm 57(21):1963-1971. • Dale D, Federman D. 2007. ACP Medicine. volume I, 3rd ed. New York: WebMD Inc. • Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Dec 2007. Arch Womens Ment Health 10(16): 247-257. • De Lorenzi DR, Baracat EC, Saciloto B, Padilha I Jr. Factors related to quality of life in post-menopause. Sep-Oct 2006. Rev Assoc Med Bras 52(5):312-7. • Dull P. Hormone replacement therapy. Dec 2006. Prim Care. 33(4):953-63. • Elsabagh S, Hartley DE, File SE. Cognitive function in late versus early postmenopausal stage. Jan 2007. Maturitas 56(1):84-93. • Encyclopædia Britannica 1911. Brown-Séquard, Charles Edward. Available at: http://en.wikipedia.org/wiki/Charles-%C3%89douard_Brown-S%C3%A9quard. Accessed on 2/29/08. • Ettinger B, Barrett-Connor E, Hoq LA, Vader JP, Dubois RW. When is it appropriate to prescribe postmenopausal hormone therapy. May-Jun 2006. Menopause 13(3):404-10. • FDA. Menopause Medicines to Help You. 2007. Available at: http://www.fda.gov/womens/medicinecharts/menopause.html. Accessed on 2/29/08. • Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Mar-Apr 2007. Hum Reprod Update 13(2):175-87. • Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jul 2002. JAMA 288(1):49-57. • Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE, Geisinger KR. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. 2000 Jun. Control Clin Trials 21(3):257-85. • Hillier, S. 100 years of hormones 1905-2005: pathway biology as the fifth force in endocrinology. 2005. J Endocrinol 184:3-4. • Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J.Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Sep 2005. Maturitas 52(1):11-7. • Howland, R., Mycek, M. 2006. Lippincott’s Illustrated Reviews: Pharmacology. 3rd ed. Maryland: Lippincott Williams & Wilkins. • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Aug 1998. JAMA 280(7):605-13. • Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jul 2002. JAMA 288(1):58-66. • Jovanovic K, Taylor HS. Individual dose response of insulin resistance to estrogen therapy. Aug 2007. J Reprod Med 52(8):667-9.

  16. Kahn A. Regaining lost youth: the controversial and colorful beginnings of hormone replacement therapy in aging. Feb 2005. J Gerontol A Biol Sci Med Sci 60(2):142-7. • Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Jan 2003. Ann Intern Med 138(1):1-9. • Koledova VV, Khalil RA. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. July 2007. Expert Rev Cardiovasc Ther. 5(4):777-89. • Krug R, Born J, Rasch B. A 3-day estrogen treatment improves prefrontal cortex-dependent cognitive function in postmenopausal women. 2006 Sep. Psychoneuroendocrinology 31(8):965-75. • Lamy C. Postmenopausal hormone therapy and vascular risk. 2007 Sep. Rev Neurol (Paris) 163(8-9):851-6. • Lobo, R. Postmenopausal hormones and coronary artery disease potential benefits and risks. Oct 2007. Climacteric Suppl 2:21-6. • Majumdar, S., Almasi, E., Stafford, R. Promotion of hormone therapy after report of harm by WHI. Oct 2004. JAMA 292(16): 1983-1988. • NewYork Presbyterian: the University Hospital of Columbia and Cornell. Hormone replacement therapy: controversy over hormone replacement therapy. Available at: http://www.nyp.org/health/women_hrt.html. Accessed on: 2/29/08. • NIH. Facts about menopausal hormone therapy. Updated June 2005. Available at: http://www.nhlbi.nih.gov/health/women/pht_facts.pdf. Accessed on 2/29/08. • PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Jan 1995. JAMA 273(3) • PEPI Trial Writing Group. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. Feb 1996. JAMA 275(5). • Pinesa A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Jun 2007. Climacteric 10(3):181-94. • Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Ehrlich K. Night sweats, sleep disturbance, and depression associated with diminished libido in late menopausal transition and early postmenopause: baseline data from the Herbal Alternatives for Menopause Trial (HALT). Jun 2007. Am J Obstet Gynecol 196(6):593.e1-7. • Rosano GM, Vitale C, Fini M.Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? 2006 Dec. Ann N Y Acad Sci 1092:341-8. • Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. 2002. JAMA 288(3): 321–333. • Santoro N. The menopausal transition. 2005 Dec 19. Am J Med 118 Suppl 12B:8-13. • Shore WS, DeLateur BJ. Prevention and treatment of frailty in the postmenopausal woman. Aug 2007. Phys Med Rehabil Clin N Am 18(3):609-21, xii. • Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. 2007. Clin Interv Aging 2(3):283-97. • Studd J. Variations on hormone replacement therapy: An answer to the 'one dose fits all' Women's Health Initiative study. Nov 2007. Gynecol Endocrinol 23(11):665-71. • The Hormone Foundation. Evolution of Estrogen. 2008. Available at: http://www.hormone.org/Menopause/estrogen_timeline/index.cfm. Accessed 2/29/08. • Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. May 2006. J Bone Miner Res 21(5):765-71. • U.S. Census Bureau international database. Population Pyramid 2007. Available at: http://www.census.gov/ipc/www/idb/country/usportal.html. Accessed on: 2/29/08. • Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Aug 2005. Health Qual Life Outcomes 3:47. • Utian WH. NIH and WHI-time for a mea culpa and steps beyond. Nov-Dec 2007. Menopause 14(6):1056-9. • Vaskivuo TE, Tapanainen JS. Apoptosis in the human ovary. Jan-Feb 2003. Reprod Biomed Online. 6(1):24-35. • Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW; WISDOM group. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Aug 2007. BMJ 335(7613):239. • Williams RE, Kalilani L, Dibenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Dec 2007. Maturitas 58(4): 348-58. • Windmaier, E., Raff, H., Strang, K. 2006. Vander’s Human Physiology: the Mechanisms of Body Function. 10th ed. New York: McGraw Hill.

More Related